ReviewWorld journal of transplantation2012
Current state of renal transplant immunosuppression: Present and future.
Review in World journal of transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Immunosuppressant management in palliative care: a systematic review.BMC palliative care · 2025Pooled it
- Predictors of Long-Term Kidney Transplant Survival: A Scoping Review.Health science reports · 2026Review
- Clinical Characteristics, Long-Term Pharmacokinetics, and Outcomes in Kidney Transplant Recipients from an African Tertiary Centre: A 10-Year Single-Centre Retrospective Review.Pharmaceutics · 2026Article
- Understanding the role of non-HLA antibodies in kidney transplantation: a literature review.Frontiers in immunology · 2026Review
- Cost Impact of a Novel Pre-transplant Risk Assessment Tool for Early Acute Rejection in Kidney Transplant Patients.Journal of health economics and outcomes research · 2026Article
- Pulmonary edema in Dengue: a systematic review and meta-analysis.Le infezioni in medicina · 2026Review
- PTEN-loss confers dependence on the guanylate synthesis enzyme IMPDH in T-cell acute lymphoblastic leukemia.bioRxiv : the preprint server for biology · 2025Article
- Refining tacrolimus dosing through CYP3A5 pharmacogenetics in Taiwanese renal transplant recipients.Renal failure · 2025Article
- Immunosuppressive treatment patterns in kidney transplant recipients in France: an insurance claims database study (OISTER) over a 12 year period.Journal of nephrology · 2025Article
- Immunosuppressive and antiinfectious regimens in vascular composite allograft recipients-a systematic review.Frontiers in transplantation · 2025Review
- Article
- Use of Donor-derived Cell-free DNA to Inform Tapering of Immunosuppression Therapy in Kidney Transplant Recipients: An Observational Study.Transplantation direct · 2024Article
- Long-term Prolonged-release Tacrolimus-based Immunosuppression in De Novo Kidney Transplant Recipients: 5-Y Prospective Follow-up of Patients in the ADVANCE Study.Transplantation direct · 2023Article
- Outcomes Among Undocumented Immigrant Kidney Transplant Recipients in California.JAMA network open · 2023Article
- Psychosocial predictors in upper-extremity vascularized composite allotransplantation: A qualitative study of multidimensional experiences including patients, healthcare professionals, and close relatives.Frontiers in psychology · 2023Article
- Fatal Case of EBV-negative Posttransplant Lymphoproliferative Disorder With Hemophagocytic Lymphohistiocytosis in an Adult Kidney Transplant Recipient.Transplantation direct · 2022Article
- Hypertension in kidney transplant recipients.World journal of transplantation · 2022Review
- Retrospective Study from a Single Center in Romania of 347 Renal Transplant Patients Treated with Tacrolimus, Mycophenolate, and Steroids to Evaluate the Association Between Anti-HLA Antibodies and 5-Year Graft Survival.Annals of transplantation · 2022Article
- Surgical Management of Lower Extremity Wounds in the Solid Organ Transplant Patient Population: Surgeon Beware.Advances in wound care · 2022Observational
- The Impact of Human Microbiotas in Hematopoietic Stem Cell and Organ Transplantation.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For kidney transplant recipients, immunosuppression commonly consists of combination treatment with a calcineurin inhibitor, an antiproliferative agent and a corticosteroid. Many medical centers use a sequential immunosuppression regimen where an induction agent, either an anti-thymocyte globulin or interleukin-2 receptor antibody, is given at the time of transplantation to prevent early acute rejection which is then followed by a triple immunosuppressive maintenance regimen. Very low rejection rates have been achieved at many transplant centers using combinations of these agents in a variety of protocols. Yet, a large number of recipients suffer chronic allograft injury and adverse events associated with drug therapy. Regimens designed to limit or eliminate calcineurin inhibitors and/or corticosteroid use are actively being pursued. An ideal immunosuppressive regimen limits toxicity and prolongs the functional life of the graft. This article contains a critical analysis of clinical data on currently available immunosuppressive strategies and an overview of therapeutic moieties in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.